Nov 2026· European Journal of Preventive Cardiology· 0 citations
Medicine
TL;DR
PCSK9-targeting therapies were associated with lower all-cause mortality and fewer ischemic events across trial populations, and the predominant contribution of large cardiovascular outcome trials enrolling populations with known atherosclerosis and using PCSK9 antibodies limits the ability to infer a survival benefit.
Abstract
Aims
To evaluate the association of PCSK9-targeting therapies with mortality and cardiovascular events in stable or clinically stabilized randomized trial populations.
Methods
We systematically reviewed randomized trials comparing alirocumab, evolocumab or inclisiran with placebo or active control. The review was registered in PROSPERO (CRD420261395609). Treatment effects were pooled as incidence rate ratios (IRRs) using random-effects models. The primary outcome was all-cause mortality. Prespecified subgroup analyses were based on trial-level known atherosclerosis status, as defined by enrollment criteria.
Results
Thirty-two trials enrolled 77,178 participants. Individual atherosclerosis status could not be determined beyond trial-level eligibility criteria. Mortality estimates were predominantly informed by large cardiovascular outcome trials. All-cause mortality was lower with PCSK9-targeting therapy (IRR 0.88, 95% CI 0.82-0.95). Estimates favored PCSK9-targeting treatment in both trials requiring known atherosclerosis for enrollment (IRR 0.90, 95% CI 0.83-0.98) and trials without such an enrollment requirement (IRR 0.78, 95% CI 0.62-0.97; interaction p = 0.21). PCSK9-targeting treatment additionally reduced myocardial infarction, stroke, and coronary revascularization rates. Leave-one-out estimates remained directionally consistent.
Conclusion
PCSK9-targeting therapies were associated with lower all-cause mortality and fewer ischemic events across trial populations. The predominant contribution of large cardiovascular outcome trials enrolling populations with known atherosclerosis and using PCSK9 antibodies limits the ability to infer a survival benefit in populations not selected on the basis of atherosclerosis status and across individual therapies, particularly inclisiran.
Summary Background Comparative effectiveness across lipid-lowering drug classes in primary prevention remains uncertain. Methods We conducted a random-effects network meta-analysis of randomised trials of lipid-lowering therapy in adults without a prior coronary event, stratified by baseline atherosclerotic cardiovascu...
Mirudhula Gnanavelou, G. Ho, Cheng-Han Ng et al.· EClinicalMedicine· 0 citations
BACKGROUND
Cardiovascular death (CVD) remains a leading cause of global mortality. Although semaglutide reduces major adverse cardiovascular events (MACE), the consistency and exact magnitude of its standalone effect on CVD across various patient phenotypes require comprehensive evaluation. This meta-analysis systemati...
G. Marino, S. Aquilani, S. D. Di Fusco et al.· Critical Pathways in Cardiol...· 0 citations
Enlicitide produced substantial reductions in LDL‐C and other atherogenic lipid parameters without an apparent increase in adverse events, and findings should be interpreted cautiously given the limited number of trials, moderate heterogeneity, and reliance on surrogate endpoints.
M. Farhan, M. Murtaza, Muhammad Mujtaba Rasool et al.· Endocrinology, Diabetes & Me...· 0 citations
Cardiovascular disease remains the leading cause of mortality worldwide. Semaglutide, a GLP-1 receptor agonist, has shown cardiovascular benefits, but its safety profile, including risks of various adverse events, in adults with established atherosclerotic cardiovascular disease (ASCVD) requires systematic evalua...
K. Keswani, M. Reddy, A. Aslam et al.· European Heart Journal· 0 citations
Baxdrostat was effective in lowering systolic blood pressure, but increased the risk of hyperkalemia, which supports it as an alternative therapy for uncontrolled and resistant hypertension, with cautious use in patients at risk for hyperkalemia.
A. Bortolotto, P. Goncalves, L. Bortolotto· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.